Although gene, cell, and protein-based therapies are in development for patients suffering from epidermolysis bullosa simplex (EBS), new pharmacological treatments are in dire need. Characterizing molecular changes in EBS, including gene expression, can identify new therapeutic targets and drugs that modulate those targets. However, sifting through gene expression information to identify the most promising drug targets is a complex data challenge. The goal of the study will identify a computational approach to evaluate and identify existing drugs approved for other diseases that can be repurposed for EBS patients. The study will perform an unprecedented characterization of gene expression changes in EBS patients compared to healthy, non-EBS individuals across multiple tissues. Using a validated computational drug discovery platform, researchers will analyze gene expression and drug data using unique algorithms. In the first year, a list of ten, safety drugs more probable to treat the EBS disease state will be identified. The most promising drugs discovered will then be tested in the clinic setting.